Literature DB >> 4378429

Formation of slow-reacting substance of anaphylaxis in human lung tissue and cells before release.

R A Lewis, S I Wasserman, E J Goetzi, K F Austen.   

Abstract

The capacity to extract slow-reacting substance of anaphylaxis (SRS-A) from human lung tissue or cells after immunologic activation, together with the measurement of SRS-A in both the extract and the surrounding fluid, permits study of total SRS-A generation. That the material extracted is SRS-A was established by both differential bioassay and purification. SRS-A accumulation was entirely intracellular after limited IgE-dependent direct or reversed anaphylactic activation. Intracellular accumulation also generally preceded release, with generation of SRS-A continuing well beyond a plateau in the cellular SRS-A level and the release of preformed mediators. The quantity of SRS-A generated after immunologic activation was modulated by the introduction of exogenous cyclic nucleotides, revealing a site of cyclic nucleotide action distinct from that on mediator release. The capacity to determine not only the release of preformed mediators but also the generation of a newly formed mediator, the sum of SRS-A in cells and supernate, adds an additional dimension to the analysis of the cellular events of immediate hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4378429      PMCID: PMC2139726          DOI: 10.1084/jem.140.5.1133

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock.

Authors:  W E BROCKLEHURST
Journal:  J Physiol       Date:  1960-06       Impact factor: 5.182

2.  The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis.

Authors:  R P Orange; R C Murphy; M L Karnovsky; K F Austen
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

3.  Immunologic release of chemical mediators from human nasal polyps.

Authors:  M Kaliner; S I Wasserman; K F Austen
Journal:  N Engl J Med       Date:  1973-08-09       Impact factor: 91.245

4.  Dispersal of rabbit lung into individual viable cells: a new model for the study of lung metabolism.

Authors:  K G Gould; J A Clements; A L Jones; J M Felts
Journal:  Science       Date:  1972-12-15       Impact factor: 47.728

5.  Release of histamine and slow reacting substance of anaphylaxis (SRS-A) by IgE-anti-IgE reactions on monkey mast cells.

Authors:  T Ishizaka; K Ishizaka; H Tomioka
Journal:  J Immunol       Date:  1972-02       Impact factor: 5.422

6.  Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate.

Authors:  R P Orange; W G Austen; K F Austen
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

7.  Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP.

Authors:  R P Orange; M A Kaliner; P J Laraia; K F Austen
Journal:  Fed Proc       Date:  1971 Nov-Dec

8.  Pharmacologic inhibition of the antigen-induced release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung tissues mediated by human IgE.

Authors:  T Ishizaka; K Ishizaka; R P Orange; K F Austen
Journal:  J Immunol       Date:  1971-05       Impact factor: 5.422

9.  Antigen induced release of histamine and SRS-A from human lung passively sensitized with reaginic serum.

Authors:  P Sheard; P G Killingback; A M Blair
Journal:  Nature       Date:  1967-10-21       Impact factor: 49.962

10.  Antigen-induced release of slow reacting substance of anaphylaxis (SRS-A rat) in rats prepared with homologous antibody.

Authors:  R P Orange; M D Valentine; K F Austen
Journal:  J Exp Med       Date:  1968-04-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Pharmacological studies of pulmonary anaphylaxis in vitro: a review.

Authors:  P O Ogunbiyi; P Eyre
Journal:  Agents Actions       Date:  1985-12

2.  Release of elastase from purified human lung mast cells and basophils. Identification as a Hageman factor cleaving enzyme.

Authors:  H L Meier; E S Schulman; L W Heck; D MacGlashan; H H Newball; A P Kaplan
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

3.  Arylsulfatase B of human lung. Isolation, characterization, and interaction with slow-reacting substance of anaphylaxis.

Authors:  S I Wasserman; K F Austen
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

4.  Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells.

Authors:  B A Jakschik; S Falkenhein; C W Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

Review 5.  Slow-reacting substance of anaphylaxis.

Authors:  P J Piper
Journal:  Ann R Coll Surg Engl       Date:  1978-05       Impact factor: 1.891

Review 6.  Pharmacologic modulation of inflammatory mediator release by rat mast cells.

Authors:  T J Sullivan; C W Parker
Journal:  Am J Pathol       Date:  1976-11       Impact factor: 4.307

7.  Generation of leukotriene C4 from a subclass of mast cells differentiated in vitro from mouse bone marrow.

Authors:  E Razin; J M Mencia-Huerta; R A Lewis; E J Corey; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Release of a slow-reacting substance from rabbit platelets.

Authors:  J M Mencia-Huerta; L Hadji; J Benveniste
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

9.  The influence of a new corticosteroid, budesonide, on anaphylactic bronchoconstriction and SRS-A release in the guinea pig.

Authors:  K Forsberg; L Sörenby
Journal:  Agents Actions       Date:  1981-07

10.  Pharmacological characterization of mediators and vagal influence in the acute allergic bronchoconstriction in guinea pigs.

Authors:  M H Vargas; L M Montaño; B Vanda; P Segura; M Selman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.